Comparison of hydromorphone continuous subcutaneous infusion and basal rate subcutaneous infusion plus PCA in cancer pain: a pilot study

Pain ◽  
1993 ◽  
Vol 53 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Marie-Claude Vanier ◽  
Gaston Labrecque ◽  
Dolorès Lepage-Savary ◽  
Éric Poulin ◽  
Louise Provencher ◽  
...  
Keyword(s):  
Pilot Study ◽  
Cancer Pain ◽  
Subcutaneous Infusion ◽  
Basal Rate ◽  
Continuous Subcutaneous Infusion

Continuous Subcutaneous Infusion of Ketorolac in Cancer Neuropathic Pain Unresponsive to Opioid and Adjuvant Drugs. A Case Report

1996 ◽  
Vol 82 (4) ◽  
pp. 413-415 ◽  
Author(s):  
Carla Ripamonti ◽  
Chiara Ticozzi ◽  
Ernesto Zecca ◽  
Carlos H. Rodriguez ◽  
Franco De Conno
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Side Effects ◽  
Cancer Patient ◽  
Cancer Pain ◽  
Antidepressant Drugs ◽  
Analgesic Efficacy ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion ◽  
Nonopioid Analgesic

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.

Continuous Subcutaneous Infusion of Buprenorphine for Cancer Pain Control

1989 ◽  
Vol 5 (2) ◽  
pp. 147-152 ◽  
Author(s):  
Junko Noda ◽  
Shinichiro Umeda ◽  
Toshiyuki Arai ◽  
Akihiro Harima ◽  
Kenjiro Mori
Keyword(s):  
Cancer Pain ◽  
Pain Control ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion

Patient-Controlled Subcutaneous Hydromorphone Verus Continuous Subcutaneous Infusion for the Treatment Cancer Pain

1988 ◽  
Vol 80 (14) ◽  
pp. 1152-1154 ◽  
Author(s):  
E. bruera ◽  
C. Brenneis ◽  
M. Michaud ◽  
k. MacMillan ◽  
J. Hanson ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion

Long-term Continuous Subcutaneous Infusion of Ketoprofen Combined With Morphine: A Safe and Effective Approach to Cancer Pain

2010 ◽  
Vol 26 (4) ◽  
pp. 267-274 ◽  
Author(s):  
Nora Maria Moselli ◽  
Mariaenrica Cruto ◽  
Paolo Massucco ◽  
Maurizio Savojardo ◽  
Felicino Debernardi
Keyword(s):  
Cancer Pain ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion

scholarly journals Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: A preliminary report

1994 ◽  
Vol 9 (2) ◽  
pp. 119-121 ◽  
Author(s):  
Franco De Conno ◽  
Ernesto Zecca ◽  
Cinzia Martini ◽  
Carla Ripamonti ◽  
Augusto Caraceni ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Preliminary Report ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion

scholarly journals Use of parecoxib by continuous subcutaneous infusion for cancer pain in a hospice population

2017 ◽  
Vol 8 (1) ◽  
pp. 25-29 ◽  
Author(s):  
Peter Armstrong ◽  
Pauline Wilkinson ◽  
Noleen K McCorry
Keyword(s):  
Cancer Pain ◽  
Cancer Diagnosis ◽  
Chart Review ◽  
Retrospective Chart Review ◽  
Subcutaneous Infusion ◽  
Opioid Dose ◽  
Local Site ◽  
Pain Scores ◽  
Continuous Subcutaneous Infusion ◽  
Sparing Effect

ObjectivesTo characterise the use of the parenteral non-steroidal anti-inflammatory drug parecoxib when given by continuous subcutaneous infusion (CSCI) in a hospice population. Clinical experience suggests parecoxib CSCI may be of benefit in this population, but empirical evidence in relation to its safety and efficacy is lacking.MethodsRetrospective chart review of patients with a cancer diagnosis receiving parecoxib CSCI from 2008 to 2013 at the Marie Curie Hospice, Belfast. Data were collected on treatment regime, tolerability and, in patients receiving at least 7 days treatment, baseline opioid dose and changes in pain scores or opioid rescue medication requirements.ResultsParecoxib CSCI was initiated in 80 patients with a mean administration of 17.9 days (median 11, range 1–94). When used for a period of 7 days, there was a statistically significant reduction in pain scores (p=0.002) and in the number of rescue opioid doses required (p=0.001), but no statistically significant opioid-sparing effect (p=0.222). It was generally well tolerated, although gastrointestinal, renal adverse effects and local site irritation were reported.ConclusionsParecoxib may have a valuable place in the management of cancer pain, especially towards the end of life when oral administration is no longer possible and CSCI administration is relied on. Further studies into the efficacy and tolerability of parecoxib CSCI are merited.

scholarly journals Ketorolac: Continuous subcutaneous infusion for cancer pain

1997 ◽  
Vol 13 (6) ◽  
pp. 315-316 ◽  
Author(s):  
Andrew Hughes ◽  
Andrew Wilcock ◽  
Ray Corcoran
Keyword(s):  
Cancer Pain ◽  
Subcutaneous Infusion ◽  
Continuous Subcutaneous Infusion
Sign in / Sign up

Export Citation Format

Share Document